SPXL, COST, JNJ, PG: ETF Outflow Alert
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 06 2025
0mins
Source: NASDAQ.COM
SPXL Share Price Analysis: SPXL's current share price is $179.99, situated between its 52-week low of $87.08 and high of $190.72, with the 200-day moving average being a key technical analysis tool.
ETFs Trading Dynamics: Exchange traded funds (ETFs) function like stocks, trading in units that can be created or destroyed based on investor demand, affecting the underlying holdings significantly during notable inflows or outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 238.330
Low
190.00
Averages
218.50
High
240.00
Current: 238.330
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TALVEY and DARZALEX Combination Therapy Significantly Improves Outcomes in Multiple Myeloma Patients
- Clinical Trial Results: Johnson & Johnson's MonumenTAL-3 study demonstrates that the combination of TALVEY and DARZALEX significantly reduces the risk of disease progression or death by 72% in patients with relapsed/refractory multiple myeloma, highlighting the efficacy of this regimen.
- Survival Rate Improvement: At 24 months, the progression-free survival rate for the TALVEY and DARZALEX combination reaches 81.3%, compared to only 51.2% for standard treatment, indicating the potential of this new therapy in earlier lines of treatment.
- Safety Analysis: While the side effects of the TALVEY and DARZALEX combination align with the known safety profiles of each monotherapy, the Tal-DP group shows a significantly lower risk of severe infections compared to standard treatment, indicating better tolerability.
- Market Outlook: Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for the TALVEY and DARZALEX combination therapy, which is expected to accelerate the market introduction of this treatment and further solidify its leadership position in the multiple myeloma treatment landscape.
See More
Johnson & Johnson Acquires Firefly Bio to Boost Cancer Drug Development
- Oncology Market Potential: Precedence Research indicates that the global oncology market is currently valued at nearly $280 billion and is projected to reach $700 billion by 2035, presenting significant growth opportunities for Johnson & Johnson.
- Acquisition Strategy: Johnson & Johnson's recent $1 billion acquisition of Firefly Bio aims to leverage its unique Firelink degrader antibody conjugate platform, focusing on treating KRAS tumors, thereby enhancing its competitive edge in cancer therapeutics.
- Technological Innovation: The Firelink platform enhances the efficacy of antibody-drug conjugates by targeting specific proteins on tumor cells, which is expected to drive J&J towards its goal of achieving $50 billion in annual oncology revenue by 2030.
- Market Outlook: The global antibody-drug conjugate market is projected to reach $21 billion by 2030 and $35 billion by 2035, meaning that the more effective J&J's ADC portfolio becomes, the more secure its market share and revenue targets will be.
See More
Paths to Achieving $3,000 Monthly in Dividends
- Conservative Investment Path: To achieve $3,000 monthly in dividends at a 3.5% yield, approximately $1,028,571 must be invested, relying on dividend aristocrats and broad dividend-growth funds; despite Johnson & Johnson's current yield of only 2.3%, its 64 consecutive years of dividend growth indicate stability.
- Moderate Path Selection: At a 6% yield, the required capital drops to $600,000, primarily depending on net-lease REITs and high-yield consumer goods; although dividend growth tends to be slower, it provides relatively stable cash flow.
- Aggressive Path Risks: With a 10% yield, an investment of $360,000 can yield $3,000 monthly, but such investments often come with the risk of capital return, and dividends may be cut during economic downturns, necessitating careful selection.
- Growth Advantage Analysis: While high-yield investments offer more income in the short term, sustained dividend growth can significantly enhance income; a 3.5% portfolio could increase annual income from $35,000 to $70,000 over a decade, showcasing the power of compounding.
See More
Goldman Sachs Identifies High-Potential Stocks
- BrightSpring Health Services: Goldman Sachs initiated coverage with a buy rating and a $71 price target, highlighting its differentiated offerings in elder care that are expected to drive growth, with shares up 67% in 2026.
- Samsara Growth Potential: Analysts at Goldman Sachs view Samsara as one of the most defensible growth assets in software, anticipating improved profit margins, with shares rising 18% over the past month, recommending investors buy on any weakness.
- Ulta Beauty Market Share: Goldman Sachs believes Ulta is well-positioned to gain market share despite a 23% decline in stock this year, citing strong performance and share repurchase plans, with a target price of $652 indicating significant upside.
- Nvidia Investment Confidence: Goldman Sachs reiterated its buy rating on Nvidia, asserting that improved capital allocation will boost investor confidence, with growth expected to continue into 2027, with estimates over 30% above market expectations.
See More
Johnson & Johnson's Talvey Therapy Significantly Reduces Mortality Risk in Multiple Myeloma
- Clinical Trial Results: Johnson & Johnson's bispecific T-cell engager Talvey, in combination with Halozyme's Darzalex Faspro, demonstrated a mortality risk reduction of up to 53% in late-stage multiple myeloma trials, highlighting its therapeutic potential.
- Survival Rate Improvement: With a median follow-up of two years, approximately 89% of patients treated with Talvey plus Darzalex Faspro were alive at 24 months, compared to 79% in the standard treatment group, indicating a significant advantage in patient survival.
- Progression-Free Survival: The combination therapy achieved an 81% progression-free survival (PFS) rate, while the standard treatment group only reached 51%, showcasing the new therapy's effectiveness in delaying disease progression.
- Label Expansion Application: Johnson & Johnson has sought label expansions for Talvey plus Darzalex Faspro in the U.S. and EU, targeting relapsed/refractory multiple myeloma patients who have previously received at least one line of therapy, further enhancing market potential.
See More
New Therapy Significantly Improves Outcomes in Multiple Myeloma
- Clinical Trial Results: Johnson & Johnson's MonumenTAL-3 study shows that the combination of TALVEY® and DARZALEXFASPRO® reduces the risk of disease progression or death by up to 72%, and the risk of death by 53% compared to standard treatment, providing a new therapeutic option for multiple myeloma patients.
- Survival Rate Improvement: At 24 months, the progression-free survival rate for TALVEY® combined with DARZALEXFASPRO® reached 81.3%, compared to only 51.2% for standard treatment, indicating the potential of this new therapy to change treatment strategies in earlier lines of therapy.
- Safety Analysis: The combination of TALVEY® and DARZALEXFASPRO® demonstrated a safety profile consistent with each monotherapy, with the Tal-D arm showing the lowest risk of severe infections, suggesting that this combination may enhance patient adherence to treatment due to its manageable safety profile.
- Regulatory Application Progress: Based on these positive clinical results, Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA, aiming to expedite the market availability of the TALVEY® and DARZALEXFASPRO® combination therapy to meet the urgent needs of multiple myeloma patients.
See More
TALVEY and DARZALEX Combination Therapy Significantly Improves Outcomes in Multiple Myeloma Patients
- Clinical Trial Results: Johnson & Johnson's MonumenTAL-3 study demonstrates that the combination of TALVEY and DARZALEX significantly reduces the risk of disease progression or death by 72% in patients with relapsed/refractory multiple myeloma, highlighting the efficacy of this regimen.
- Survival Rate Improvement: At 24 months, the progression-free survival rate for the TALVEY and DARZALEX combination reaches 81.3%, compared to only 51.2% for standard treatment, indicating the potential of this new therapy in earlier lines of treatment.
- Safety Analysis: While the side effects of the TALVEY and DARZALEX combination align with the known safety profiles of each monotherapy, the Tal-DP group shows a significantly lower risk of severe infections compared to standard treatment, indicating better tolerability.
- Market Outlook: Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for the TALVEY and DARZALEX combination therapy, which is expected to accelerate the market introduction of this treatment and further solidify its leadership position in the multiple myeloma treatment landscape.
See More
Johnson & Johnson Acquires Firefly Bio to Boost Cancer Drug Development
- Oncology Market Potential: Precedence Research indicates that the global oncology market is currently valued at nearly $280 billion and is projected to reach $700 billion by 2035, presenting significant growth opportunities for Johnson & Johnson.
- Acquisition Strategy: Johnson & Johnson's recent $1 billion acquisition of Firefly Bio aims to leverage its unique Firelink degrader antibody conjugate platform, focusing on treating KRAS tumors, thereby enhancing its competitive edge in cancer therapeutics.
- Technological Innovation: The Firelink platform enhances the efficacy of antibody-drug conjugates by targeting specific proteins on tumor cells, which is expected to drive J&J towards its goal of achieving $50 billion in annual oncology revenue by 2030.
- Market Outlook: The global antibody-drug conjugate market is projected to reach $21 billion by 2030 and $35 billion by 2035, meaning that the more effective J&J's ADC portfolio becomes, the more secure its market share and revenue targets will be.
See More
Paths to Achieving $3,000 Monthly in Dividends
- Conservative Investment Path: To achieve $3,000 monthly in dividends at a 3.5% yield, approximately $1,028,571 must be invested, relying on dividend aristocrats and broad dividend-growth funds; despite Johnson & Johnson's current yield of only 2.3%, its 64 consecutive years of dividend growth indicate stability.
- Moderate Path Selection: At a 6% yield, the required capital drops to $600,000, primarily depending on net-lease REITs and high-yield consumer goods; although dividend growth tends to be slower, it provides relatively stable cash flow.
- Aggressive Path Risks: With a 10% yield, an investment of $360,000 can yield $3,000 monthly, but such investments often come with the risk of capital return, and dividends may be cut during economic downturns, necessitating careful selection.
- Growth Advantage Analysis: While high-yield investments offer more income in the short term, sustained dividend growth can significantly enhance income; a 3.5% portfolio could increase annual income from $35,000 to $70,000 over a decade, showcasing the power of compounding.
See More
Goldman Sachs Identifies High-Potential Stocks
- BrightSpring Health Services: Goldman Sachs initiated coverage with a buy rating and a $71 price target, highlighting its differentiated offerings in elder care that are expected to drive growth, with shares up 67% in 2026.
- Samsara Growth Potential: Analysts at Goldman Sachs view Samsara as one of the most defensible growth assets in software, anticipating improved profit margins, with shares rising 18% over the past month, recommending investors buy on any weakness.
- Ulta Beauty Market Share: Goldman Sachs believes Ulta is well-positioned to gain market share despite a 23% decline in stock this year, citing strong performance and share repurchase plans, with a target price of $652 indicating significant upside.
- Nvidia Investment Confidence: Goldman Sachs reiterated its buy rating on Nvidia, asserting that improved capital allocation will boost investor confidence, with growth expected to continue into 2027, with estimates over 30% above market expectations.
See More
Johnson & Johnson's Talvey Therapy Significantly Reduces Mortality Risk in Multiple Myeloma
- Clinical Trial Results: Johnson & Johnson's bispecific T-cell engager Talvey, in combination with Halozyme's Darzalex Faspro, demonstrated a mortality risk reduction of up to 53% in late-stage multiple myeloma trials, highlighting its therapeutic potential.
- Survival Rate Improvement: With a median follow-up of two years, approximately 89% of patients treated with Talvey plus Darzalex Faspro were alive at 24 months, compared to 79% in the standard treatment group, indicating a significant advantage in patient survival.
- Progression-Free Survival: The combination therapy achieved an 81% progression-free survival (PFS) rate, while the standard treatment group only reached 51%, showcasing the new therapy's effectiveness in delaying disease progression.
- Label Expansion Application: Johnson & Johnson has sought label expansions for Talvey plus Darzalex Faspro in the U.S. and EU, targeting relapsed/refractory multiple myeloma patients who have previously received at least one line of therapy, further enhancing market potential.
See More
New Therapy Significantly Improves Outcomes in Multiple Myeloma
- Clinical Trial Results: Johnson & Johnson's MonumenTAL-3 study shows that the combination of TALVEY® and DARZALEXFASPRO® reduces the risk of disease progression or death by up to 72%, and the risk of death by 53% compared to standard treatment, providing a new therapeutic option for multiple myeloma patients.
- Survival Rate Improvement: At 24 months, the progression-free survival rate for TALVEY® combined with DARZALEXFASPRO® reached 81.3%, compared to only 51.2% for standard treatment, indicating the potential of this new therapy to change treatment strategies in earlier lines of therapy.
- Safety Analysis: The combination of TALVEY® and DARZALEXFASPRO® demonstrated a safety profile consistent with each monotherapy, with the Tal-D arm showing the lowest risk of severe infections, suggesting that this combination may enhance patient adherence to treatment due to its manageable safety profile.
- Regulatory Application Progress: Based on these positive clinical results, Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA, aiming to expedite the market availability of the TALVEY® and DARZALEXFASPRO® combination therapy to meet the urgent needs of multiple myeloma patients.
See More
